REFERENCES

• Fernandez-CordobaELopez-IborAlino JLa monoclorimipramina en enfermos psiquiatricos resistentes a otros tratamientos. Acta Luso-Esp Neurol Psiquiatr Ciene Afines.196726119147
   PubMedGoogle Scholar
• Van Renynghede Voxvrie GAnafranil (G34586) in obsessive neurosis. Acta Neurol Psychiatr Belg.1968687877924976729
   PubMedGoogle Scholar
• RackMChirDExperience with intravenous clomipramine. In: Obsessional States and their Treatment with Anafranil. Manchester, UK: Geigy;.1970
   Google Scholar
• ThorenPAsbergMCronholmBJornestedtLTraskmanLClomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry.198022667687
   Google Scholar
• MarksIMSternRSMawsonDet al.Clomipramine and exposure for obsessive-compulsive rituals: i. Br J Psychiatry.19801361256986939
   PubMed Web of Science ®Google Scholar
• MontgomerySAClomipramine in obsessional neurosis: a placebo-controlled trial. Pharmacol Med.19801189192
   Google Scholar
• El Mansari MBlierPMechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry.20063036237316427729
   PubMed Web of Science ®Google Scholar
• WinslowJTInselTRNeurobiology of obsessive compulsive disorder: a possible role for serotonin. J Clin Psychiatry.199051(suppl)2731 2199432
   PubMed Web of Science ®Google Scholar
• BarrLCGoodmanWKPriceLHMcDougleCJCharneyDSThe serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. J Clin Psychiatry.199253(suppl)17281532961
   PubMed Web of Science ®Google Scholar
• GoddardAWShekharAWhitemanAFMcDougleCJSerotonergic mechanisms in the treatment of obsessive-compulsive disorder. Drug Discov Today.20081332533218405845
   PubMed Web of Science ®Google Scholar
• ZoharJInselTRObsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry.1987226676873036259
   PubMed Web of Science ®Google Scholar
• DenysDZoharJWestenbergHGThe role of dopamine in obsessivecompulsive disorder: preclinical and clinical evidence. J Clin Psychiatry.200465(suppl 14)111715554783
   PubMed Web of Science ®Google Scholar
• HarsányiACsigóKDemeterGNémethANew approach to obsessivecompulsive disorder: dopaminergic theories. Psychiatr Hung.20072224825818167420
   PubMedGoogle Scholar
• PittengerCKrystalJHCoricVGlutamate-modulating durgs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx.20063698116490414
   PubMedGoogle Scholar
• BhattacharyyaSChakrabortyKGlutamatergic dysfunction - newer targets for anti-obsessional drugs. Recent Pat CNS Drug Discov.20072475518221217
   PubMedGoogle Scholar
• DenysDvanMegen HWestenbergHThe adequacy of pharmacotherapy in outpatients with obsessive-compulsive disorder. Int J Clin Psychopharmacol.200217 109115
   PubMed Web of Science ®Google Scholar
• HuppertJDSchultzLTFoaEBet al.Differential response to placebo among patients with social phobia, panic disorder, and obsessive compulsive disorder. Am J Psychiatry.20041611485148715285978
   PubMed Web of Science ®Google Scholar
• BlandRCNewmanSCOmHAge and remission of psychiatric disorders. Can J Psychiatry.1997427227299307832
   PubMed Web of Science ®Google Scholar
• SteinDJIpserJCBaldwinDSBandelowBTreatment of obsessive-compulsive disorder. CNS Spectr.200712(suppl 3)283517277721
   PubMed Web of Science ®Google Scholar
• BaldwinDSAndersonIMNuttDJet al.Evidence-based guidelines fort he pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol.20051956759616272179
   PubMed Web of Science ®Google Scholar
• NICE clinical guideline 31 Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. 2005 Available at: www. Nice.org.uk
   Google Scholar
• CanadianPsychiatric AssociationClincial Practice Guidelines: management of anxiety disorders. Can J Psychiatry.200651(suppl 2)S9S91
   Google Scholar
• American Psychiatric Association: Practice guidelines for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry.2007164 (suppl 1)15617202533
   PubMed Web of Science ®Google Scholar
• BandelowBZoharJHollanderEet al.World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders first revision. W J Biol Psychiatry.20089248312
   PubMed Web of Science ®Google Scholar
• FinebergNAPampaloniIPallantiSIpserJSteinDJSustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder. Int Clin Psychopharmacol.20072231332217917549
   PubMed Web of Science ®Google Scholar
• SteinDJAndersenEWTonnoirBFinebergNEscitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetinereferences, fixed-dose, 24-week study. Curr Med Res Opin.20072370171117407626
   PubMed Web of Science ®Google Scholar
• SoomroGMAltmannDGRajagopalSOakley-BrowneMSelective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev.20081
   Google Scholar
• McDougleCJGoodmanWKLeckmanJFPriceLHThe psychopharmacology of obsessive-compulsive disorder implications for treatment and pathogenesis. Psychiatr Clin North Am.1993167497668309811
   PubMed Web of Science ®Google Scholar
• FallonBALiebowitzMRCampeasRet al.Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine a placebo-controlled study. Arch Gen Psychiatry.1998559189249783563
   PubMed Web of Science ®Google Scholar
• KoranLNSalleeFRPallantiSRapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry.19971543964019054789
   PubMed Web of Science ®Google Scholar
• PallantiSQuercioliLKoranLMCitalopram intravenous infusion in resistant obsessive-compulsive disorder an open trial. J Clin Psychiatry.20026379680112363120
   PubMed Web of Science ®Google Scholar
• NinanPTKoranLMKievAet al.High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry.200667152216426083
   PubMed Web of Science ®Google Scholar
• Rabinowitz IBaruch YBarakYHigh-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol.200832495318090508
   PubMed Web of Science ®Google Scholar
• DoughertyDDJamessonMDeckersbachTet al.Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol.20092430631119730388
   PubMed Web of Science ®Google Scholar
• KoranLMSaxenaSIssues and strategies in treating refractory obsessive-compulsive disorder. CNS Spectr.200252431
   Web of Science ®Google Scholar
• FinebergNAGaleTMEvidence-based pharmacotherapy of obsessivecompulsive disorder. Int J Neuropsychopharmacol.2005810712915450126
   PubMed Web of Science ®Google Scholar
• MarazzitiDGoliaFConsoliGet al.Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectr.20081397197619037176
   PubMed Web of Science ®Google Scholar
• BrowneMHornEJonesTTThe benefits of clomipramine-fluoxetine combination in obsessive-compulsive disorder. Can J Psychiatry.1993382422438518974
   PubMed Web of Science ®Google Scholar
• RavizzaLBarzegaGBellinoSBogettoFMainaGDrug treatment of obsessive compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull.1996321671738927668
   PubMed Web of Science ®Google Scholar
• BlochMHLanderos-WeisenbergerAKelmendiBCorkVBrackenMBLeckmanJFA systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry.20061162263216585942
   PubMed Web of Science ®Google Scholar
• IpserJCCareyPDhansayYFakierNSeedatSSteinDJPharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev.2006 DC005473
   Web of Science ®Google Scholar
• SkapinakisPPapatheodorouTMavreasVAntipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol.2007177993 16904298
   PubMed Web of Science ®Google Scholar
• FinebergNSteinDJCareyPet al.Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol.20062133734317012980
   PubMed Web of Science ®Google Scholar
• DenysDFinebergNCareyPDSteinDJQuetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry.20076141241417241831
   PubMed Web of Science ®Google Scholar
• KordonAWahlKKochet al.Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychopharmacol.20082855055418794652
   PubMed Web of Science ®Google Scholar
• SavasHAYumruMOzenMEQuetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a retrospective comparative study. Clin Drug Investig.200828439442
   PubMed Web of Science ®Google Scholar
• VulnikNCDenysDFluitmanSBMeinardiJCWestenbergHGQuetiapine augments the effect of citalopram in non-refractory obsessivecompulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry.2009701001100819497245
   PubMed Web of Science ®Google Scholar
• MainaGPessinaEAlbertBogettoF8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol.20081836437218280710
   PubMed Web of Science ®Google Scholar
• MatsunagaHNagataTHayashidaKOhyaKKiriikeNSteinDJA long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry.20097086386819422759
   PubMed Web of Science ®Google Scholar
• PessinaEAlbertUBogettoFMainaGAripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol.20092426526919629012
   PubMed Web of Science ®Google Scholar
• FigéeMDenysDNew pharmacotherapeutic approaches to obsessivecompulsive disorder. CNS Spectr.200914(suppl 3)1323
   Web of Science ®Google Scholar
• ConnorKMPayneVMGaddeKMZhangWDavidsonJRThe use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry.2005664951 15669888
   PubMed Web of Science ®Google Scholar
• MetinOYaziciKTotSYaziciAEAmisulpride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol.20031846346712923825
   PubMed Web of Science ®Google Scholar
• OtsukaTTogoTSugiyamaNet al.Perspirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression. Prog Neuropsychopharmacol Biol Psychiatry.20073256456817166643
   PubMed Web of Science ®Google Scholar
• SimpsonHBFoaEBLiebowitzMRet al.A randomized, controlled trial of cognitive behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry.200816562163018316422
   PubMed Web of Science ®Google Scholar
• TundoASalvatiLBustoGDlSpigno DFalciniRAddition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study. J Clin Psychiatry.2007681552155617960971
   PubMed Web of Science ®Google Scholar
• TenneijNHvan MegenHJDenysDAWestenbergHGBehavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. J Clin Psychiatry.2005661169117516187776
   PubMed Web of Science ®Google Scholar
• TolinDFMaltbyNDiefenbachGJHannanSEWorhunskyPCognitivebehavioral therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list-controlled open trial. J Clin Psychiatry.200465922931 15291681
   PubMed Web of Science ®Google Scholar
• EddyKTDutraLBradlyR Westen DA multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev.2004241011103015533282
   PubMed Web of Science ®Google Scholar
• RothbaumBOCritical parameters for D-cycloserine enhancement of cognitive-behavioral therapy for obsessive-compulsive disorder. Am J Psychiatry.16516529329618316423
   PubMed Web of Science ®Google Scholar
• AboujaoudeEBarryJJGamelNMemantine augmentation in treatment-resistant obsessive-compulsive disorder an open label trial. J Clin Psychopharmacol.200929515519142108
   PubMed Web of Science ®Google Scholar
• PoyurovskyMWeizmanRWeizmanAKoranLMemantine for treatment-resistant OCDAm J Psychiatry.20051622191219216263867
   PubMed Web of Science ®Google Scholar
• PasquiniMBiondiMMemantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry.2006301173117516730870
   PubMed Web of Science ®Google Scholar
• GreenbergWMBenedictMMDoerferJet al.Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. J Psychiatr Res.20094366467019046587
   PubMed Web of Science ®Google Scholar
• CoricVTaskiranSPittengerCet al.Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry.20055842442815993857
   PubMed Web of Science ®Google Scholar
• EgashiraNOkunoRHaradaSet al.Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Eur J Pharmacol.200858616417018423440
   PubMed Web of Science ®Google Scholar
• HollanderEDell'OssoBTopiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol.20062118919116528143
   PubMed Web of Science ®Google Scholar
• Van AmeringenMManciniCPattersonBBennettMTopiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety.2006231516178009
   PubMed Web of Science ®Google Scholar
• OulisPMasdrakisVGKarapouliosEet al.Pregabalin augmentation to sertraline-risperidone combination in the treatment of obsessive-compulsive disorder. Prim Care Companion J Clin Psychiatry.200810249
   Google Scholar
• RoebelMNenadicISauerHPregablin as a successful pharmacotherapeutic option in OCD - a case report. Nervenarzt.200980(suppl 2)P043-007
   Google Scholar
• LafleurDLPittengerCKelmendiBet al.N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology.200618425425616374600
   PubMed Web of Science ®Google Scholar
• NorbergMMKrystalJHTolinDFA meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapyBiol Psychiatry.2008631118112618313643
   PubMed Web of Science ®Google Scholar
• StorchEAMerloLJBengtsonMetalD-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol.20072223023717519647
   PubMed Web of Science ®Google Scholar
• KushnerMGKimSWDonahueCetalD-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry.20071583583817588545
   PubMed Web of Science ®Google Scholar
• WilhelmSBuhlmannUTolinDFetalAugmentation of behavior therapy with D-cycloserin for obsessive-compulsive disorder. Am J Psychiatry.200816533534118245177
   PubMed Web of Science ®Google Scholar
• KoranLMQuirkTLorberbaumJPElliottMMirtazapine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol.20012153753911593084
   PubMed Web of Science ®Google Scholar
• KoranLMGamelNNChoungHWSmithENAboujaoudeENMirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry.20056651552015816795
   PubMed Web of Science ®Google Scholar
• PallantiSQuercioliLBruscoliMResponse acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry.2004651394139915491244
   PubMed Web of Science ®Google Scholar
• Flaischer-GrinbergSKlavirOJoelDThe role of 5-HT2A and 5-HT2C receptors in the signal attenuation rat model of obsessive-compulsive disorder. Int J Neuropsychopharmacol.20081181182518339223
   PubMed Web of Science ®Google Scholar
• VallejoJOlivaresJMarcosTBulbenaAMechónJMClomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial. Br J Psychiatry.19921616656701422616
   PubMed Web of Science ®Google Scholar
• JenikeMABaerLMinichielloWERauchSLButtolphMLPlacebo-controlled trial of fluoxetine and phenelzine for obesessive-compulsive disorder. Am J Psychiatry.19971 54 126112649286186
   PubMed Web of Science ®Google Scholar
• KobakKATaylorLVBystritskyAetalSt John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol.20052029930416192837
   PubMed Web of Science ®Google Scholar
• HermeshHAizenbergDMunitzHTrazodone treatment in clomipramine-resistant obsessive-compulsive disorder. Clin Neuropharmacol.1990133223282119885
   PubMed Web of Science ®Google Scholar
• MarazzitiDGemignaniADell'ossoLTrazodone augmentation in OCD: a case series report. CNS Spectr.19994484918311107
   PubMedGoogle Scholar
• PigottTAL'HeureuxFRubensteinCSBernsteinSEHillJLMurphyDLA double-blind, placebo-controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol.1992121561621629380
   PubMed Web of Science ®Google Scholar
• DenysDvan derWee Nvan MegenJHWestenbergHGA double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol.20032356857514624187
   PubMed Web of Science ®Google Scholar
• AlbertUAgugliaEMainaGBogettoFVenlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12 week, controlled study. J Clin Psychiatry.2002631004100912444814
   PubMed Web of Science ®Google Scholar
• HollanderEFriedbergJWassermanSAllenABirnbaumMKoranLMVenlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry.20036454655012755657
   PubMed Web of Science ®Google Scholar
• Dell'OssoBMundoEMarazzitiDAltamuraACSwitching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol.20082221021318208931
   PubMed Web of Science ®Google Scholar
• YehYWChenCHKuoSCWangSCChenCKFengHMHigh-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission. Clin Neuropharmacol.20093217417619483491
   PubMed Web of Science ®Google Scholar
• FontenelleLFMendlowiczMVMiguelECVersianiMCitalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder. World J Biol Psychiatry.20056575916097406
   PubMed Web of Science ®Google Scholar
• DannonPNSassonYHirschmannSlancuIGrunhausLJZoharJPindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol.20001016516910793318
   PubMed Web of Science ®Google Scholar
• BlierPBergeronRSequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol.19961137448732312
   PubMed Web of Science ®Google Scholar
• MundoEGuglielmoEBellodiLEffect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol.1998132192249817627
   PubMed Web of Science ®Google Scholar
• PigottTALHeureuxFHillJLBihariKBernsteinSEMurphyDLA double-blind study of adjuvant buspirone hydrochloride in clomipraminetreated patients with obsessive-compulsive disorder. J Clin Psychopharmacol.1992121181552034
   PubMed Web of Science ®Google Scholar
• McDougleCJPriceLHGoodmanWKCharneyDSHeningerGRA controlled trail of lithium augmentation in fluvoxamine-refractory obsessivecompulsive disorder: lack of efficacy. J Clin Psychopharmacol.1991111751841820757
   PubMed Web of Science ®Google Scholar
• PigottTAPatoMTL'HeureuxFetalA controled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol.1991112422481918422
   PubMed Web of Science ®Google Scholar
• CrockettBAChurchillEDavidsonJRA double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Ann Clin Psychiatry.20041612713215517844
   PubMedGoogle Scholar
• HewlettWAVinogradovSAgrasWSClomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol.1992124204301474179
   PubMed Web of Science ®Google Scholar
• HollanderEKaplanAStahlSMA double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry.200344034
   Web of Science ®Google Scholar
• GoldsmithTBShapiraNAKeckPERapid remission of OCD with tramadol hydrochloride. Am J Psychiatry.199915666066110200754
   PubMed Web of Science ®Google Scholar
• KoranLMAboujaoudeEBullockKDFranzBGamelNElliottMDouble-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry.20056635335915766302
   PubMed Web of Science ®Google Scholar
• AmiazRFostickLGershonAZoharJNaltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol.200818455461 18353618
   PubMed Web of Science ®Google Scholar
• OnderETuralUGôkbakanMDoes gabapentin lead to early symptom improvement in obsessive-compulsive disorder? Eur Arch Psychiatry Clin Neurosci.200825831932318297416
   PubMed Web of Science ®Google Scholar
• DeltitoJAValproate pretreatment for the difficult-to-treat patient with OCD. J Clin Psychiatry.1994555007989288
   PubMed Web of Science ®Google Scholar
• Corá-LocatelliGGreenbergBDMartinJDMurphyDLValproate monotherapy in an SRI-intolerant OCD patient. J Clin Psychiatry.19985982
   PubMed Web of Science ®Google Scholar
• HewlettWASchmidSPSalomonRMPilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry.2003641025103014628977
   PubMed Web of Science ®Google Scholar
• PallantiSBernardiSAntoniniSSinghNHollanderEOndansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs.2009231047105519958042
   PubMed Web of Science ®Google Scholar
• YoungCRBosticJQMcDonaldCLClozapine and refractory obsessivecompulsive disorder: a case report. J Clin Psychopharmacol.1994142092118027421
   PubMed Web of Science ®Google Scholar
• SteinertTSchmitt-MichelPOKaschkaWPConsiderable improvement in a case of obsessive-compulsive disorder in an emotionally unstable personality disorder, borderline type under tretment with clozapine. Pharmacopsychiatry.199629 1111148738316
   PubMed Web of Science ®Google Scholar
• PoyurovskyMClozapine in treatment-refractory obsessive-compulsive disorder with comorbid schizotypal personality disorder. Isr J Psychiatry Relat Sci.20084521922019398826
   PubMed Web of Science ®Google Scholar
• CasasMAlvarezEDuroPetalAntiandrogenic treatment of obsessive-compulsive neurosis. Acta Psychiatry Scand.198673221222
   PubMed Web of Science ®Google Scholar
• ErikssonTAnti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of long-acting gonadotropin-releasing hormone analogue triptorelin. Int Clin Psychopharmacol.200722576117159461
   PubMed Web of Science ®Google Scholar
• MorenoFAWiegandCBTaitanoEKDelgadoPLSafety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry.2006671735174017196053
   PubMed Web of Science ®Google Scholar
• Salin-PascualRJBasanez-VillaEChanges in compulsion and anxiety symptoms with nicotine transdermal patches in non-smoking obsessive-compulsive disorder patients. Rev Invest Clin.20035565065415011734
   PubMedGoogle Scholar
• LundbergSCarlssonANorfeldtPCarlssonMLNicotine treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry.2004281195119915610934
   PubMed Web of Science ®Google Scholar
• PasquiniMGarviniABiondiMNicotine augmentation for refractory obsessive-compulsive disorder. A case report. Prog Neuropsychopharmacol Biol Psychiatry.20052915715915610960
   PubMed Web of Science ®Google Scholar
• eedatSSteinDJInositol augmentation of serotonin reuptake inhbitors in treatment-refractory obsessive-compulsive disorder: an open trial. Int Clin Psychopharmacol.19991435335610565802
   PubMed Web of Science ®Google Scholar
• FuxMBenjaminJBelmakerRHInositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. Int J Neuropsychopharmacol.1999219319511281989
   PubMed Web of Science ®Google Scholar
• InselTRHamiltonJAGuttmacherLBMurphyDLD-amphetamine in obsessive-compulsive disorder. Psychopharmacology.1983802312356412267
   PubMed Web of Science ®Google Scholar
• KoranLMAboujaoudeEGamelNNDouble-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry.2009701530153519573497
   PubMed Web of Science ®Google Scholar
• RavizzaLBarzegaGBellino S, Gogetto F, Maina G. Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry.1995563683737635854
   PubMed Web of Science ®Google Scholar
• rzegovesiSCavalliniMCCavediniPDiaferiaGLocatelliMBellodiLClinical predictors of drug response in obesessive-compulsive disorder. J Clin Psychopharmacol.20012148849211593074
   PubMed Web of Science ®Google Scholar
• SteinDJMontgomerySAKasperSTanghoyPPredictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. Int Clin Psychopharmacol.20011635736111712625
   PubMed Web of Science ®Google Scholar
• DenysDBurgerHvan MegenHde GeusFWestenbergHA score for predicting response to pharmacotherapy in obsessive-compulsive disorder. Int Clin Psychopharmacol.20031831532214571151
   PubMed Web of Science ®Google Scholar
• HollanderEKaplanASchmeidlerJetalNeurological soft signs as predictors of treatment response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci.200517427477
   Web of Science ®Google Scholar
• ShettiCNReddyYCKandavelTet al.Clinical predictors of drug nonresponse in obsessive-compulsive disorder. J Clin Psychiatry.2005661517152316401151
   PubMed Web of Science ®Google Scholar
• StorchEALarsonMJShapiraNAetalClinical predictors of early fluoxetine treatment response in obsessive-compulsive disorder. Depress Anxiety.20062342943316841343
   PubMed Web of Science ®Google Scholar
• TükelRBozkurtOPolatAGencAAtliHClinical predictors of response to pharmacotherapy with selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Psychiatry Clin Neurosci.20066040440916884439
   PubMed Web of Science ®Google Scholar
• Mataix-ColsDRauchSLManzoPAJenikeMABaerLUse of factoranalyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry.19991561409141610484953
   PubMed Web of Science ®Google Scholar
• SteinDJAndersenEWOveroKFResponse to symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo. Rev Bras Psiquiatr.20072930330718200396
   PubMed Web of Science ®Google Scholar
• SaxenaSBrodyALMaidmentKMBaxterLRParoxetine treatment of compulsive hoarding. J Psychiatry Res.200741481487
   PubMed Web of Science ®Google Scholar
• Di BellaDErzegovesiSCavalliniMCBellodiLObsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response. Pharmacogenomics J.2002217618112082589
   PubMedGoogle Scholar
• BillettEARichterMAKingNHeilsALeschKPKennedyJLObsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene. Mol Psychiatry.199724034069322235
   PubMed Web of Science ®Google Scholar
• DenysDVan NieuwerburghFDeforceDWestenbergHGPrediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry.20076874775317503984
   PubMed Web of Science ®Google Scholar
• itterlWAignerMStompeTetalChanges in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Neuropsychopharmacology.2008333126313418354388
   PubMed Web of Science ®Google Scholar
• BaxterLRSchwartzJMBergmanKSetalCaudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry.1992496816891514872
   PubMed Web of Science ®Google Scholar
• SaxenaSBrodyALHoMLZohrabiMMaidmentKMBaxterLRDifferential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry.200316052253212611834
   PubMed Web of Science ®Google Scholar
• KimCHCheonKAKooMSetalDopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors. Neuropsychobiology.2007 5515616217657168
   PubMed Web of Science ®Google Scholar
• HurleyRASaxenaSRauchSLHoehn-SaricRTaberKHPredicting treatment response in obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci.20021424925312154147
   PubMed Web of Science ®Google Scholar
• umitaniSHaradaMKuboHOhmoriTProton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive-compulsive disorder patients. Psychiatry Res.2007154859217208418
   PubMed Web of Science ®Google Scholar